SLC35A4 Inhibitors
SLC35A4 inhibitors encompass a variety of compounds that target specific cellular processes and pathways to attenuate the functionality of the SLC35A4 protein. Substances that disrupt the Golgi apparatus, such as those altering the protein glycosylation process, are particularly impactful. These inhibitors can lead to the improper glycosylation of SLC35A4, which is essential for its stability and function. This disruption can result in SLC35A4 proteins that are either misfolded or improperly localized, rendering them dysfunctional. Similarly, inhibitors that target glycoprotein processing enzymes in the endoplasmic reticulum cause misfolding of SLC35A4, leading to degradation or inactivation of the protein. Microtubule and actin polymerization disruptors also play a significant role in SLC35A4 inhibition by impairing intracellular trafficking pathways that are crucial for the correct localization and function of SLC35A4. These inhibitors can cause SLC35A4 to be mislocalized, which impacts its role in solute transport.
Additionally, compounds that inhibit energy production within the cell can indirectly impact SLC35A4 function due to the energy-dependent nature of its transport mechanism. For example, glucose analogs that hinder glycolysis can reduce the energy availability for SLC35A4's transport activities. Furthermore, agents that alter the pH of endosomal and lysosomal compartments interfere with the normal processing and trafficking oflysosomal enzymes, which can have repercussions on the functionality and localization of the SLC35A4 protein. This disturbance can negate SLC35A4's ability to mediate the transport of specific solutes, effectively inhibiting its physiological role.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
This compound disrupts the function of the Golgi apparatus, which could affect the glycosylation process that SLC35A4 might be involved in. Disruption of glycosylation can lead to improper function or localization of SLC35A4. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $135.00 $246.00 $619.00 $799.00 $1796.00 | 6 | |
An inhibitor of glycosylation; by inhibiting mannosidase II, it alters the glycoprotein processing, potentially leading to misfolded SLC35A4 proteins that are unable to carry out their transport function effectively. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Inhibits N-linked glycosylation by blocking the first step in the synthesis of the lipid-linked oligosaccharide precursor, which can result in improperly glycosylated SLC35A4, affecting its stability and function. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $180.00 $620.00 | 10 | |
A glucosidase inhibitor that affects glycoprotein processing in the endoplasmic reticulum, potentially leading to misfolded SLC35A4 proteins that are degraded or non-functional. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
A carboxylic ionophore that disrupts Golgi apparatus function and could therefore affect the post-translational modification, including glycosylation, of SLC35A4, potentially leading to dysfunctional protein. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $72.00 $142.00 | ||
An inhibitor of glucosidases, which could lead to improper folding of glycoproteins like SLC35A4 during their maturation, affecting their stability and transport function. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $132.00 $529.00 $1005.00 $6125.00 | 25 | |
A mannosidase I inhibitor that can prevent the proper processing of glycoproteins, potentially leading to a misfolded and dysfunctional SLC35A4. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $98.00 $315.00 $2244.00 $4396.00 $17850.00 $34068.00 | 3 | |
By disrupting microtubule polymerization, colchicine can interfere with intracellular transport processes, potentially affecting the trafficking and function of SLC35A4. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
An actin polymerization inhibitor; this can lead to altered cytoskeletal dynamics and could affect the trafficking of membrane proteins like SLC35A4, potentially leading to their mislocalization and dysfunction. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
By disrupting microtubule dynamics, nocodazole can impair intracellular trafficking, potentially affecting the proper localization and function of SLC35A4. | ||||||